A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Wake Forest University Health Sciences
Thomas Jefferson University
M.D. Anderson Cancer Center
Bristol-Myers Squibb
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
European Myeloma Network B.V.
University of Turin, Italy
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Janssen Research & Development, LLC
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
University of Chicago
Janssen Research & Development, LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Regeneron Pharmaceuticals
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Washington University School of Medicine
Janssen Research & Development, LLC
Janssen Research & Development, LLC
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Case Comprehensive Cancer Center
Hackensack Meridian Health
University Hospital, Toulouse
Regeneron Pharmaceuticals
University Hospital, Lille
University Hospital, Lille
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Beth Israel Deaconess Medical Center
Mayo Clinic
The First Hospital of Jilin University
American Society of Clinical Oncology
Memorial Sloan Kettering Cancer Center